Eruptive lentiginosis confined to areas of regressing psoriatic plaques after adalimumab treatment
An. bras. dermatol; 96 (1), 2021
Results: 16
Análise do perfil clínico e epidemiológico de pacientes com artrite psoriásica em ambulatório de reumatologia na Região Amazônica
Rev. Soc. Bras. Clín. Méd; 19 (3), 2021
Objetivo: Conhecer o perfil clínico e epidemiológico de pacien-
tes portadores de artrite psoriásica de uma região brasileira.
Método: Pesquisa observacional, transversal, epidemiológica
e documental, baseada na coleta de dados obtidos a partir da
análise de 53 prontuários de pacientes cadastra...
Estudios Transversales, Registros Médicos/estadística & datos numéricos, Perfil de Salud, Artritis Psoriásica/epidemiología, Brasil/epidemiología, Hospitales Universitarios/estadística & datos numéricos, Reumatología, Distribución por Edad y Sexo, Hipertensión, Dislipidemias, Diabetes Mellitus, Obesidad, Artritis Psoriásica/complicaciones, Artritis Psoriásica/tratamiento farmacológico, Antirreumáticos/uso terapéutico, Inhibidores del Factor de Necrosis Tumoral/uso terapéutico, Artritis Psoriásica/sangre, Sedimentación Sanguínea, Inhibidores de Interleucina/uso terapéutico, Proteína C-Reactiva/análisis, Colesterol/sangre, Triglicéridos/sangre, Glucemia/análisis, Psoriasis/complicaciones
Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens
Clinics; 76 (), 2021
The appropriate dosing regimens of secukinumab for psoriatic arthritis (PsA) are not well defined. We performed a meta-analysis to evaluate the efficacy and safety of different dosing regimens of secukinumab in the treatment of PsA. A systematic search was conducted using major electronic databases to id...
Immunogenicity to biological drugs in psoriasis and psoriatic arthritis
Clinics; 76 (), 2021
Monoclonal antibodies or fusion proteins, defined as biological drugs, have modified the natural history of numerous immune-mediated disorders, allowing the development of therapies aimed at blocking the pathophysiological pathways of the disease, providing greater efficacy and safety than conventional t...
Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto
Rev. méd. Chile; 148 (5), 2020
The financial coverage granted by law in Chile for patients with psoriatic arthritis who require biological treatment is of paramount importance and a great advance. However physicians must be knowledgeable about the advantages and limitations of this therapy. The challenge of clinicians is to choose the...
Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area
Clinics; 75 (), 2020
OBJECTIVES: To retrospectively evaluate the performance and distinctive pattern of latent tuberculosis (TB) infection (LTBI) screening and treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) under anti-tumor necrosis factor (TNF) therapy and determine the relevance of re-...
Artritis Psoriásica/diagnóstico, Artritis Psoriásica/tratamiento farmacológico, Artritis Psoriásica/epidemiología, Estudios de Seguimiento, Tuberculosis Latente/diagnóstico, Tuberculosis Latente/epidemiología, Estudios Retrospectivos, Espondilitis Anquilosante/tratamiento farmacológico, Espondilitis Anquilosante/epidemiología, Inhibidores del Factor de Necrosis Tumoral/uso terapéutico
Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional disease-modifying anti-rheumatic drugs in an endemic area
Clin. biomed. res; 40 (1), 2020
Introduction: Registries of spondyloarthritis (SpA) patients’ follow-up provided evidence that tumor necrosis factor inhibitors (TNFi) increase the incidence of active tuberculosis infection (TB). However, most of these registries are from low burden TB areas. Few studies evaluated the safety of biolog...
Antirreumáticos/efectos adversos, Tuberculosis/epidemiología, Tuberculosis/inducido químicamente, Espondiloartritis/tratamiento farmacológico, Incidencia, Inhibidores del Factor de Necrosis Tumoral/efectos adversos, Productos Biológicos/efectos adversos, Tuberculosis Latente/tratamiento farmacológico, Inhibidores del Factor de Necrosis Tumoral/uso terapéutico, Antirreumáticos/uso terapéutico, Artritis Psoriásica/tratamiento farmacológico, Espondilitis Anquilosante/tratamiento farmacológico, Productos Biológicos/uso terapéutico, Enfermedades Endémicas, Estudios Retrospectivos, Estudios de Seguimiento
Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up
An. bras. dermatol; 94 (4), 2019
Certolizumabe pegol para o tratamento de artrite psoriásica em pacientes adultos com resposta inadequada a medicamentos modificadores do curso da doença
CONTEXTO: O tratamento medicamentoso da AP inclui anti-inflamatórios não esteroidais (AINE), glicocorticoides e medicamentos modificadores do curso da doença (MMCD) sintéticos e biológicos (medicamentos anti-TNF). Os medicamentos biológicos são indicados em caso de falha ao tratamento prévio com ...
¿Es efectivo el ustekinumab para la artritis psoriásica que no responde a tratamiento inicial?
Medwave; 18 (2), 2018
INTRODUCCIÓN: La artritis psoriásica es una artritis inflamatoria sin una clara etiología, con el tratamiento biológico como un pilar fundamental en pacientes más complejos. Existen varias alternativas para tratamiento biológico, debido a su alto costo, es importante evaluar la real efectividad de ...
Artritis Psoriásica/tratamiento farmacológico, Fármacos Dermatológicos/uso terapéutico, Ustekinumab/uso terapéutico, Artritis Psoriásica/fisiopatología, Bases de Datos Factuales, Fármacos Dermatológicos/efectos adversos, Ensayos Clínicos Controlados Aleatorios como Asunto, Resultado del Tratamiento, Ustekinumab/efectos adversos